lyxumia
sanofi winthrop industrie - lixisenatide - diabetes mellitus, type 2 - drugs used in diabetes, glucagon-like peptide-1 (glp-1) analogues - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.
quinsair
chiesi farmaceutici s.p.a - levofloxacin - cystic fibrosis; respiratory tract infections - antibakterielle midler for systemisk bruk, - quinsair er indisert for behandling av kronisk lunge infeksjoner forårsaket av pseudomonas aeruginosa hos voksne pasienter med cystisk fibrose. det bør vurderes å offisielle retningslinjer for riktig bruk av antibakterielle midler.
cetraxal comp 3 mg/ ml / 0.25 mg/ ml
poa pharma scandinavia ab - ciprofloksacinhydroklorid / fluocinolonacetonid - Øredråper, oppløsning - 3 mg/ ml / 0.25 mg/ ml
depo-medrol 40 mg/ ml
pfizer as - metylprednisolonacetat - injeksjonsvæske, suspensjon - 40 mg/ ml
gallium (ga67) citrate 37 mbq/ ml
mallinckrodt medical b.v. - gallium (67ga) sitrat - injeksjonsvæske, oppløsning - 37 mbq/ ml
methylprednisolone orion 4 mg
orion corporation orion pharma, espoo - metylprednisolon - tablett - 4 mg
methylprednisolone orion 16 mg
orion corporation orion pharma, espoo - metylprednisolon - tablett - 16 mg
prednisolon 20 mg
orifarm healthcare a/s - prednisolon - tablett - 20 mg
prednisolon 2.5 mg
orifarm healthcare a/s - prednisolon - tablett - 2.5 mg
prednisolon 5 mg
orifarm healthcare a/s - prednisolon - tablett - 5 mg